Wednesday, September 17, 2014
Inquirer Daily News

Time for clear laws on stem cell research

Is it legal for the federal government to fund human embryonic stem cell research? Next month, a federal appeals court will hear arguments, yea and nay. Any decision is sure to be appealed because current laws are ambiguous. And that's the problem, said John Gearhart, head of the University of Pennsylvania's Institute for Regenerative Medicine - and one of the first two scientists to isolate human embryonic stem cells in 1998. "We need a comprehensive national policy on all human embryo research with appropriate, unequivocal laws," he said last week. "Congress has no stomach to take this up."

Time for clear laws on stem cell research

Is it legal for the federal government to fund human embryonic stem cell research?

Next month, a federal appeals court will hear arguments, yea and nay. Any decision is sure to be appealed because current laws are ambiguous.

And that's the problem, said John Gearhart, head of the University of Pennsylvania's Institute for Regenerative Medicine - and one of the first two scientists to isolate human embryonic stem cells in 1998.

"We need a comprehensive national policy on all human embryo research with appropriate, unequivocal laws," he said last week. "Congress has no stomach to take this up."

Gearhart understands some people have moral objections to destroying early embryos to get their "pluripotent" cells - blank slates capable of replicating indefinitely, and spinning off all types of more mature cells.

But he also knows researchers are far from understanding pluripotency well enough to harness its healing power.

For example, Gearhart said, it has become clear that "embryonic stem cells are states, not entities."

Even though they exist only briefly in a hundred-cell embryo, they play a molecular symphony, chemically cueing some genes to play, while silencing others. If the cells are removed early in the symphony, they are different than at the end.

No wonder some embryonic stem cell colonies, or "lines," replicate well in lab dishes, while most lines morph unpredictably into more specialized cells, or die.

These barely understood genetic cues are also complicating the discovery that specialized cells, such as skin cells, can be reprogrammed to regress to a pluripotent state - no embryos needed.

"Induced pluripotent stem cells," or IPS, tend to revert to, or at least recall, their original specialty, Gearhart said. (It's like forcing a pastry chef to be a short-order cook; he can't resist substituting crepes for pancakes.)

IPS cells gradually lose this memory, but not until they have replicated many times, becoming truly blank slates.

"The technology to detect all these changes "is not easy," Gearhart said. With so much to discover, it's time to end the legal ambiguity.

 

About this blog

Check Up covers major health events in our region and offers everything from personal health advice to an expert look at health reform. Read about some of our bloggers here.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section

Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Latest Health Videos
Also on Philly.com:
Stay Connected